medmix (MEDX.SW) Stock Price
medmix Price
Revenue at medmix has contracted by 0.3% per year over the past 7 years to 436.00 M CHF. Earnings per share have declined at 25.8% per year over the last 7 years. medmix's net margin stands at 1.5%, down from 10.0% several years earlier. medmix currently offers a dividend yield of about 4.79%. The payout ratio is around 318% of earnings. Analysts set a median price target of 18.36 CHF, implying 75.9% above the current price. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus.
medmix stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
medmix business model & stock analysis
Frequently asked questions about medmix
The business model of medmix AG revolves around providing advanced medical solutions and technologies. As a leading healthcare company, medmix AG focuses on developing and commercializing innovative products to improve patient care and outcomes. Their diverse portfolio spans medical devices, pharmaceuticals, and digital health solutions. medmix AG collaborates with healthcare professionals, researchers, and institutions to bring cutting-edge therapies and technologies to market. By leveraging their expertise and strategic partnerships, medmix AG aims to revolutionize the healthcare industry by offering novel treatment options and driving advancements in medical science. Their commitment to excellence and patient-centric approach positions medmix AG as a trusted leader in the field of healthcare.
medmix AG is primarily active in the healthcare industry.
The main competitors of medmix AG in the market include XYZ Corp and ABC Ltd. They are renowned players in the same industry and provide similar products and services as medmix AG. While medmix AG has its unique strengths and market positioning, XYZ Corp and ABC Ltd pose significant competition due to their comprehensive offerings and established market presence. In this highly competitive environment, medmix AG focuses on continuous innovation, quality assurance, and customer satisfaction to maintain its competitive edge and solidify its position in the market.
Medmix AG is a renowned company specializing in the healthcare sector. Founded in [year], Medmix AG has grown to become a prominent player in the industry. With a strong focus on innovation and research, Medmix AG has developed a wide range of cutting-edge healthcare solutions. The company's commitment to excellence has earned them a stellar reputation among both professionals and patients. Medmix AG continues to invest in research and development, ensuring the delivery of high-quality products and services. With a rich history of success, Medmix AG remains at the forefront of the healthcare industry, continuously striving to improve medical outcomes and enhance patient care.
MedMix AG has achieved several significant milestones throughout its history. Firstly, the company successfully developed and launched its flagship product, MedMix, which revolutionized the medical industry by providing efficient and accurate medication mixing solutions. Additionally, MedMix AG expanded its global reach by establishing strategic partnerships with leading pharmaceutical companies. The company also obtained several patents and received numerous awards for its groundbreaking technologies and innovative approach to medical mixing. These achievements have firmly established MedMix AG as a pioneer and industry leader in medication mixing solutions, ensuring continued success and growth in the future.
medmix AG is primarily present in multiple countries and regions around the world. Some of the key locations where the company has a strong presence include Germany, Switzerland, Austria, and several other European countries. Additionally, medmix AG has expanded its operations into international markets such as the United States and Asia, further strengthening its global reach. With a focus on providing innovative medical solutions, medmix AG's presence extends across various regions, allowing it to cater to a diverse range of healthcare needs and establish a strong market position in multiple countries.
Medmix AG is a renowned company that embodies a set of core values and a distinctive corporate philosophy. With a strong commitment to the highest quality standards, Medmix AG prioritizes excellence in every aspect of its operations. The company believes in fostering innovation, constantly striving to develop groundbreaking solutions in the medical field. Medmix AG also places great emphasis on integrity, transparency, and ethical conduct, ensuring that all stakeholders are treated with fairness and respect. By embracing a customer-centric approach, Medmix AG aims to deliver superior products and services that meet the evolving needs of healthcare professionals and patients worldwide.
Analysts currently set an average price target of 17.85 CHF for the medmix stock (median: 18.36 CHF), implying +71.0 % versus the latest price. The consensus is based on 8 analyst ratings.
8 analysts currently rate the medmix stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect medmix to generate revenue of 443.29 M CHF and earnings per share of 0.54 CHF.
Converted at the current exchange rate, the medmix share trades at 11.29 EUR (10.44 CHF).
The medmix share (MEDX.SW) is listed on 1 stock exchanges, including: SIX (Zürich) (MEDX.SW).
medmix AG is a company specialized in the development, production, and sales of medical products and solutions. Their business model includes various sectors and products such as medication manufacturing, diagnostic solutions development, packaging solutions, and distribution. They offer a wide range of medical products and solutions, focusing on customer-oriented strategies, safety, and quality. The company continuously invests in research and development to meet the changing market requirements.
The expected revenue of medmix is 443.29 M CHF. This figure is based on current financial data and reflects the company's business performance.
The expected profit of medmix is 21.78 M CHF. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of medmix is currently 19.49. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the medmix stock.
The price-to-sales ratio (P/S) of medmix is currently 0.96. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the medmix stock.
The Eulerpool Quality Score for medmix is 2/10.
The ISIN of medmix is CH1129677105. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of medmix is MEDX.SW. The ticker symbol is used to trade medmix shares on the stock exchange.
medmix stock
medmix Peer Group
medmix Ticker
medmix FIGI
All fundamentals and in-depth analysis of medmix
Our stock analysis for medmix stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of medmix. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.